Post: Recent publications- Anne Peters, MD

Recent publications (2021):
Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes and Severe Renal Impairment. Diabetes Obes Metab. 2021 Aug 02. Cherney DZI, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Carroll AK, Lapuerta P, Banks P, Agarwal R. PMID: 34338408. View in PubMed-

Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study. Diabetes Obes Metab. 2021 08; 23(8):1892-1901. Wilmot EG, Close KL, Jurišic-Eržen D, Bruttomesso D, Ampudia-Blasco FJ, Bosnyak Z, Roborel de Climens A, Bigot G, Peters AL, Renard E, Berard L, Calliari LE, Seufert J. PMID: 33914401. View in PubMed-

Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021 06 08; 325(22):2262-2272. Martens T, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, Pop-Busui R, Philis-Tsimikas A, Bao S, Umpierrez G, Davis G, Kruger D, Bhargava A, Young L, McGill JB, Aleppo G, Nguyen QT, Orozco I, Biggs W, Lucas KJ, Polonsky WH, Buse JB, Price D, Bergenstal RM, MOBILE Study Group . PMID: 34077499. View in PubMed-

Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor. Diabetes Spectr. 2021 Jan; 34(1):42-51. Teng R, Kurian M, Close KL, Buse JB, Peters AL, Alexander CM. PMID: 33627993. View in PubMed-


More Posts

ADA Pathway Award opportunities RFA

Please see below for two ADA Pathway Award opportunities RFA Process for Limited Submissions: PIs must submit their application as a Limited Submission through the Research Initiatives and Infrastructure Application Portal: